Back to Search
Start Over
[Bone metastasis in prostate cancer]
- Source :
- Moltzahn, F; Thalmann, G N (2012). [Bone metastasis in prostate cancer]. Urologe, 51(1), pp. 20-6. Berlin: Springer-Verlag 10.1007/s00120-011-2741-1
- Publication Year :
- 2012
- Publisher :
- Springer-Verlag, 2012.
-
Abstract
- Bone metastasis and skeletal complications have a devastating impact on the quality of life and are a major cause of morbidity in prostate cancer patients. In addition to established bone-targeted therapies, new drugs such as endothelin A receptor antagonists, MET and VEGFR-2 antagonists or radiopharmaceuticals are in the focus of development. The standard care in prostate cancer patients with bone metastases to prevent skeletal-related events (SRE) are bisphosphonates. Denosumab, a human monoclonal antibody against RANKL, appeared to be superior to zoledronic acid for prevention of SRE and has been shown to prolong bone metastases-free survival. In contrast to zoledronic acid, denosumab clearance is not dependent on kidney function and can be administered subcutaneously. Similar rates of toxicity were observed for both substances; however, long-term data for denosumab are limited.
Details
- Language :
- German
- Database :
- OpenAIRE
- Journal :
- Moltzahn, F; Thalmann, G N (2012). [Bone metastasis in prostate cancer]. Urologe, 51(1), pp. 20-6. Berlin: Springer-Verlag 10.1007/s00120-011-2741-1 <http://dx.doi.org/10.1007/s00120-011-2741-1>
- Accession number :
- edsair.doi.dedup.....073912f86061e4d0c89b9ec6d4877e90
- Full Text :
- https://doi.org/10.7892/boris.15439